Price
$75.35+2.54%Social Signal Score
Analyst Ratings
26 analystsRevenue
$2.74B+53.45%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David J. Endicott
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 25,000
- Beta
- 0.72
- Country
- CH
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.84
Financials
Revenue
$2.74B+53.4%Net Income
$260.00M-21.0%EBITDA
$676.00M+129.2%Free Cash Flow
$612.00M+134.5%EPS (diluted)
$0.54-19.4%Shares Outstanding (diluted)
483.30M-1.1%Operating Expenses
$1.19BCash & Debt
$1.81BReturn of Capital
$227.00MDividend per Share
$0.36Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.40B | $980.00M | $1.99 |
| 2024 | $9.91B | $1.02B | $2.06 |
| 2023 | $9.46B | $974.00M | $1.98 |
| 2022 | $8.72B | $335.00M | $0.68 |
| 2021 | $8.29B | $376.00M | $0.77 |
| 2020 | $6.83B | $-531.00M | $-1.09 |
| 2019 | $7.51B | $-656.00M | $-1.34 |
| 2018 | $7.15B | $-227.00M | $-0.46 |
| 2017 | $6.79B | $256.00M | $0.52 |
| 2016 | $6.60B | $-170.00M | $-0.35 |
| 2015 | $6.52B | $296.27M | $0.61 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ALC's reported EPS growth of 12.6% a year over 10 years.
- EPS in 5 years
- $3.58
- Implied price
- $143.36
- Return from $74.31
- 14.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $71.27 — -4.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| 2.6% | -3.2% | 0.6% | 3.9% | 6.9% | 9.5% |
| 7.6% | 1.5% | 5.5% | 9.0% | 12.1% | 14.9% |
| 12.6% | 6.2% | 10.4% | 14.0% | 17.3% | 20.2% |
| 17.6% | 10.9% | 15.3% | 19.1% | 22.5% | 25.5% |
| 22.6% | 15.6% | 20.2% | 24.2% | 27.7% | 30.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (19)
- News247wallst.com·1d ago·Positive
Bill Ackman Opened About $2 Billion in New Positions in Alcon and Intercontinental Exchange Pershing Square just made room for two new names in its tightly concentrated portfolio, one a cash-generating market machine and the other a beaten-down eye-care maker. Each carries a catch that retirement investors should check before copying the trade.
View source ↗ - Newsreuters.com·11d ago·Neutral
Alcon shares fall as tighter eye-care market outlook raises growth concerns Alcon shares fall as tighter eye-care market outlook raises growth concerns
View source ↗ - Newszacks.com·17d ago·Neutral
Countdown to Alcon (ALC) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Beyond analysts' top-and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
View source ↗ - Newszacks.com·17d ago·Positive
Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains? Alcon (ALC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newsseekingalpha.com·32d ago·Neutral
…e Alcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand despite recent market underperformance. ALC demonstrates steady revenue growth, improved core EPS guidance, and a pipeline of innovative products targeting high-need clinical niches like glaucoma and macular disease. Balance sheet strength is evident with investment-grade ratings and the lowest D/E ratio among peers, reducing leverage risk and enhancing the risk profile.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
…ion Offering of 6.20% Convertible Unsecured Subordinated Debentures CATHARINES, ONTARIO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Algoma Central Corporation (“Algoma”) (TSX:ALC) announced today that it has entered into an agreement to sell, on a bought deal basis to a syndicate of underwriters led by CIBC Capital Markets, $50,000,000 aggregate principal amount of 6.20% convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Public Offering”).
View source ↗ - Newsbusinesswire.com·37d ago·Negative
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
View source ↗ - Newszacks.com·40d ago·Negative
Credo Expands AI Connectivity Portfolio With 1.6T ZeroFlap ALC CRDO expands its AI connectivity portfolio with the 1.6T ZeroFlap Active Light Cable, offering lower power consumption, enhanced reliability and extended reach.
View source ↗ - Newsdefenseworld.net·46d ago·Neutral
Algoma Central (TSE:ALC) Shares Cross Above 50 Day Moving Average – Here’s Why Algoma Central Co. (TSE: ALC - Get Free Report) passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of C$23.31 and traded as high as C$23.99. Algoma Central shares last traded at C$23.90, with a volume of 4,445 shares trading hands. Algoma Central Price Performance The
View source ↗ - Newszacks.com·79d ago·Neutral
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now? Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
View source ↗ - Newsseekingalpha.com·80d ago·Positive
Alcon: A Re-Rating In Eyesight Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.
View source ↗ - Newsbusinesswire.com·88d ago·Neutral
Alcon Prices EUR 500 Million Senior Notes Offering GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
View source ↗ - Newsseekingalpha.com·97d ago·Positive
Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·103d ago·Positive
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.
View source ↗ - Newsreuters.com·103d ago·Negative
Eye care company Alcon raises profitability outlook, cuts tariff hit estimate Swiss-American eye care company Alcon on Monday hiked its profit guidance and lowered its estimate for the full-year tariff impact to $40 million to $90 million, factoring in an anticipated refund of around $60 million from the U.S. government.
View source ↗ - Newszacks.com·104d ago·Neutral
Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsbusinesswire.com·104d ago·Positive
New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth GENEVA--(BUSINESS WIRE)--New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth.
View source ↗ - Newsbenzinga.com·104d ago·Neutral
Aecom, Alcon And 3 Stocks To Watch Heading Into Monday With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $0.90 per share
Typical surprise +2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$0.91 vs $0.89beat
- Mon, Aug 10$0.84 vs $0.77beat
- Tue, May 5$0.85 vs $0.80beat
- Tue, Feb 24$0.78 vs $0.79miss
- Tue, Nov 11$0.79 vs $0.77beat
- Tue, Aug 19$0.76 vs $0.71beat
Estimates and results for ALC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 2, 2026 (28d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 9, 2026 (28d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Apr 15, 2025 (43d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (19d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (28d later)Buy$1,001 - $15,000
- Peter Meijerhouse · MI03 · disclosed Mar 16, 2021 (27d later)Sell$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (20d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (28d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 9, 2020 (37d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 9, 2020 (36d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Jun 25, 2020 (20d later)Buy$100,001 - $250,000
- Debbie Dingellhouse · MI12 · disclosed Nov 15, 2019 (14d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Apr 28, 2019 (13d later)Sell$15,001 - $50,000
- Alan Lowenthalhouse · CA47 · disclosed Apr 28, 2019 (13d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Apr 28, 2019 (13d later)Sell$15,001 - $50,000
- Debbie Dingellhouse · MI12 · disclosed Apr 18, 2019 (7d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
